- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04298203
Role of Pharmacotherapy in Counteracting Weight Regain in Adolescents With Severe Obesity
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Severe obesity, afflicting ~8% of adolescents in the U.S., is a serious and challenging medical and public health problem. The number and levels of cardiovascular risk factors are considerably higher in the context of severe obesity compared to milder forms of obesity. Approximately 85% of youth with severe obesity have ≥1 cardiovascular risk factor. Non-alcoholic fatty liver disease is highly-prevalent among adolescents with severe obesity with estimates nearing 60%. Subclinical atherosclerosis and arterial stiffening is present in youth with severe obesity at levels similar to those with type 2 diabetes. Youth with severe obesity have high levels of inflammation and oxidative stress, adverse adipokine profiles, and arterial endothelial activation. Moreover, longitudinal data implicate obesity in childhood as a strong predictor of future risk factor clustering and sub-clinical atherosclerosis in adulthood. Risk of developing type 2 diabetes is high in youth with severe obesity. Severe obesity in adolescence is associated with chronic disability from a wide range of causes later in life. Perhaps most disturbing is the poor long-term prognosis for these youth. Approximately 90% will have a BMI ≥35 kg/m2 in adulthood. Disturbingly, severe obesity in adulthood reduces life expectancy by 7-14 years.
In the field of obesity management, weight loss maintenance has proven to be an arduous challenge. Indeed, long-term weight loss maintenance is seldom achieved owing to numerous biological adaptations occurring in the post-weight loss setting. These include, but are not limited to, neuroendocrine changes in the gut-brain axis influencing appetite and satiety and reduction of energy expenditure. Following weight loss, peripheral and central mechanisms respond in a way similar to starvation by conveying a sense that energy reserves have dwindled, activating a strong and persistent counter-response to increase caloric intake. Moreover, metabolic rate decreases, further compounding the propensity for weight rebound. These counter-regulatory adaptations persist for many years following initial weight loss, and in fact might be permanent.
Adolescents with severe obesity (BMI ≥120% above the 95th percentile or BMI ≥35 kg/m2) are not immune to the vexing issue of weight regain as evidenced by the poor outcomes of interventions using lifestyle modification alone.22-25 Indeed, large clinic-based studies from Europe and the U.S. reported that only a small fraction of patients were able to achieve and maintain clinically-meaningful weight loss with lifestyle modification therapy. Metabolic/bariatric surgery is an effective treatment but uptake is very low and many pediatricians and parents are concerned about the irreversible nature of this treatment and worry about the possibility of long-term (decades) risks, which are currently unknown. Therefore, a large treatment gap exists between lifestyle modification therapy and metabolic/bariatric surgery that remains unfilled.
Pharmacotherapy has the potential to prevent weight regain by targeting counter-regulatory mechanisms in the post-weight loss setting, with various agents demonstrating improved long-term weight loss durability in adults. Unfortunately, pediatric options are limited as only one obesity medication is approved for use among adolescents for long-term use (orlistat), and is rarely prescribed because of modest efficacy and notable side effects. Among the most promising candidates in the pediatric pipeline, owing to its relatively high degree of efficacy compared to other medications, is the combination of phentermine and topiramate, which is the most effective FDA-approved adult obesity medication currently available. Placebo-subtracted weight loss at one and two years with phentermine/topiramate is 9% at the top dose in adult trials. The mechanisms of action of phentermine/topiramate, which together are thought to reduce appetite, enhance satiety, and potentially increase energy expenditure, are well-suited for the purpose of weight loss maintenance since they target many of the biological adaptations known to induce relapse and subsequent regain.
The rationale for specifically focusing on phentermine/topiramate (vs. other medications) to prevent weight regain is supported by its multiple mechanisms of action, which are thought to target many of the post-weight loss counter-regulatory biological adaptations known to induce relapse. These mechanisms include: 1) reducing appetite through inhibition of norepinephrine reuptake (phentermine) and reduction of hypothalamic glutamate neurotransmission (topiramate) and lowering the levels of neuropeptide Y (topiramate); 2) enhancing satiety by slowing gastric emptying (combination of phentermine/topiramate); and 3) increasing energy expenditure (both phentermine and topiramate independently). Through these mechanisms of action, sustained weight loss has been demonstrated with phentermine/topiramate treatment in adults. While other obesity medications target some of these pathways, their respective mechanisms of action are generally less comprehensive, and accordingly have lower efficacy, ranging from 3-5% placebo-subtracted weight reduction at 1 year.
In terms of safety, topiramate is FDA-approved in children and adolescents for the treatment of seizures and migraine headaches with a reasonable safety track-record. Importantly, the investigators observed no signal of cognitive problems in a pilot clinical trial of topiramate for the treatment of obesity. Phentermine is FDA-approved for short-term use in ages >16 years old for treatment of obesity and is the most widely-prescribed adult obesity medication in the U.S. Although in a distinct medication class, phentermine is not dissimilar in mechanism of action and side effects to many of the stimulant medications widely-prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) in youth. Adult data suggest no adverse cardiovascular effects or increased risk of addiction potential or withdrawal symptoms associated with phentermine use and the investigator's clinical experience with phentermine in adolescents with obesity demonstrated an acceptable safety profile.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Aaron Kelly, PhD
- Phone Number: 612-626-3402
- Email: kelly105@umn.edu
Study Contact Backup
- Name: Claudia Fox, MD
- Phone Number: 612-301-6616
- Email: lusc0001@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Cameron E Naughton, M.P.A.
- Phone Number: 612-625-3623
- Email: naug0009@umn.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Severe obesity (BMI >/= 120% of the 95th percentile or BMI >/= 35 kg/m2)
- Age 12 to < 18 years of age at enrollment (screening) and Tanner stage >/= 2 - Female participants who are sexually active with males and who are able to get pregnant must agree to use two forms of contraception throughout the trial
Exclusion Criteria:
- Diabetes (type 1 or 2)
- Current or recent (< six months prior to enrollment) use of anti-obesity medication(s) defined as orlistat, phentermine, topiramate, combination phentermine/topiramate, liraglutide, and/or combination naltrexone/bupropion (monotherapy use of naltrexone or bupropion is not an exclusion)
- Previous metabolic/bariatric surgery
- Current use of a stimulant medication
- History of glaucoma
- Current or recent (<14 days) use of monoamine oxidase inhibitor
- Known hypersensitivity to sympathomimetic amines
- Any history of treatment with growth hormone
- Any history of bulimia nervosa
- Major psychiatric disorder as determined by the local medical monitor
- Unstable and clinically-diagnosed (defined as documented in the medical record, if available) depression
- Any history of active suicide attempt
- History of suicidal ideation or self-harm within the previous 30 days of screening
- PHQ-9 score >15 at screening
- Current pregnancy or plans to become pregnant during study participation
- Current tobacco use
- ALT or AST >/= 3 times the upper limit of normal
- Bicarbonate <18 mmol/L
- Creatinine > 1.2 mg/dL
- Any history of seizures
- Uncontrolled hypertension as determined by the local medical monitor
- History of structural heart defect or clinically significant arrhythmia
- Diagnosed monogenic obesity
- Any history of cholelithiasis
- Any history of nephrolithiasis
- Clinically diagnosed hyperthyroidism
- Untreated thyroid disorder
- Any disorder, unwillingness, or inability, not covered by any other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Meal Replacement Therapy
Participants who are enrolled in the study will be administered a short-term (six weeks) meal replacement induction period.
Because the trial is deigned to evaluate weight loss maintenance, participants must achieve at least 5% BMI reduction at week six of the meal replacement period in order to be randomized.
Subjects will be asked to strictly follow the eating regimen, which will include a total of approximately 1,000 kcals per day of commercially-available liquid shakes (breakfast and lunch), pre-packaged frozen entrée meals for dinner, two servings of fruit, and three servings of vegetables.
Shakes/meals will be provided free of charge - fruits/vegetables will be purchased by the participants.
Guidance will be provided regarding the use of the meal replacement shakes at school, and participants will be encouraged to engage in family meal sessions despite eating different foods.
|
The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
|
Active Comparator: Phentermine/Topiramate
Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo.
Participants randomized to phentermine/topiramate will start treatment at 3.75 mg/23 mg orally once daily in the morning for 14 days, then increased to 7.5 mg/46 mg orally once daily in the morning for 14 days, then be increased to 11.25 mg/69 mg orally once daily in the morning for 14 days, then increased to 15 mg/92 mg orally once daily in the morning for the remainder of the trial.
Following the final study visit, participants will be down-titrated gradually by taking medication every other day for seven days before stopping treatment altogether.
|
The study medication to be tested for this study is a combination of phentermine and topiramate.
Other Names:
A pill that looks like Phentermine-Topiramate but has no active medication.
|
Placebo Comparator: Placebo
Participants who achieve at least 5% BMI reduction at week six of the meal replacement period will be randomized (1:1) to receive either phentermine/topiramate or placebo.
Participants randomized to the placebo will receive inert tablets that look like the active comparator.
In order to mimic the active comparator arm, subjects randomized to the placebo arm will up titrate their placebo at the beginning of the study treatment and will down titrate as in the active comparator arm.
Participants will be instructed to take the medication under the supervision of a parent/guardian and pill counts of returned product will serve as a proxy of treatment compliance.
|
The study medication to be tested for this study is a combination of phentermine and topiramate.
Other Names:
A pill that looks like Phentermine-Topiramate but has no active medication.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To measure changes in BMI.
Time Frame: 58 weeks.
|
The investigators will measure the change in BMI reduction during the meal replacement therapy intervention as well as during the treatment with phentermine/topiramate or placebo.
Weight and height will be combined to report BMI in kg/m^2
|
58 weeks.
|
To measure changes in total body fat
Time Frame: iDXA will be conducted at four timepoints (Baseline, 1 day of Randomization, Week 26 and Week 52).
|
The investigators will measure the change in total body fat during the meal replacement therapy intervention and during the treatment with phentermine/topiramate or placebo via use of dual-energy x-ray absorptiometry (iDXA).
|
iDXA will be conducted at four timepoints (Baseline, 1 day of Randomization, Week 26 and Week 52).
|
To measure changes in visceral fat.
Time Frame: iDXA will be conducted at four timepoints (Baseline, 1 day of Randomization, Week 26 and Week 52).
|
The investigators will measure the change in visceral fat during the meal replacement therapy intervention and during the treatment with phentermine/topiramate or placebo via use of the iDXA.
|
iDXA will be conducted at four timepoints (Baseline, 1 day of Randomization, Week 26 and Week 52).
|
To measure changes in lipids.
Time Frame: Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
Lipids (consisting of total lipids, LDL, HDL, cholesterol and triglycerides)
|
Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
To measure changes in glucose.
Time Frame: Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
The investigators will track whether fasting glucose levels come down during the course of participation in the study.
Glucose can be an indicator of diabetes.
Typical fasting glucose ranges for individuals 6 months and older are approximately 70-99 mg/dL.
Investigators will track whether glucose levels reduce during the course of the study.
|
Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
To measure changes in insulin.
Time Frame: Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
Investigators will track whether insulin levels reduce during the course of the study.
|
Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
To measure changes in hemoglobin A1c.
Time Frame: Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
Investigators will track whether hemoglobin A1c levels (which can indicate pre-diabetes or diabetes) decrease during the course of the study.
Normal ranges for hemoglobin A1c are less than 5/7%.
Prediabetes ranges are 5.7-7.5% and diabetes ranges are 6.5% or greater.
|
Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
To measure changes in C-reactive protein (CRP).
Time Frame: Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
C-reactive protein tests help to measure cardiac risk.
Investigators will review C-reactive protein levels during the study to see if they decrease.
Normal ranges for CRP are: <1 mg/L for low risk, 1.0-3.0
mg/L for average risk, >3.0 mg/L for high risk and > 10.0 mg/L for acute inflammation.
|
Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
To measure changes in oxidized LDL.
Time Frame: Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
Investigators will measure changes in oxidized low-density lipoprotein.
Oxidized LDL is a potentially harmful cholesterol that is produced in the body when normal LDL cholesterol is damaged by chemical interactions.
|
Baseline, 1 day of Randomization, Week 26 and Week 52 visits.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aaron Kelly, PhD, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Obesity, Morbid
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anticonvulsants
- Appetite Depressants
- Anti-Obesity Agents
- Central Nervous System Stimulants
- Sympathomimetics
- Topiramate
- Phentermine
Other Study ID Numbers
- PEDS-2020-28498
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Meal Replacement Therapy
-
University of MinnesotaCompletedPediatric Obesity | Obesity, SevereUnited States
-
Iowa State UniversityNational Institute on Aging (NIA)CompletedMild Cognitive ImpairmentUnited States
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.Recruiting
-
Children's Hospital SrebrnjakBelupo; Podravka d.d.RecruitingBody Weight | Overweight and ObesityCroatia
-
Khoo Teck Puat HospitalCompletedThe Effect of Intermittent Energy Restriction Using Meal Replacements in Overweight Chinese SubjectsObesity | FastingSingapore
-
University of North Carolina, Chapel HillCompletedOverweight | Obese | Body Composition, Beneficial | Satiety | Basal Metabolic RateUnited States
-
Teatis, IncCitruslabsNot yet recruitingDiabetes Mellitus, Type 2United States
-
Chung Shan Medical UniversityCompletedObesity | Diet Modification | Nutrient; ExcessTaiwan
-
Massachusetts General HospitalRecruitingObesity | Overweight | PreDiabetes | Diabetes Type 2United States
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingChildhood ObesityUnited States